Sbir topic 081: adjuvant development for vaccines against infectious or immune-mediated diseases
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00042
- Awardee
-
Antagen Biosciences Inc. UEI HXD6EFH2ND57
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · PHS20201 · Posted Jun 21, 2019
- Contract value 100% obligated
- $600,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 12 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Roxbury, MA 02118, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $600,000 |
About this award
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics including adjuvant development for vaccines against infectious or immune-mediated diseases. This SBIR contract will support NIAID's mission to conduct and fund research on preventing, diagnosing and treating infectious and immune-mediated diseases through Antagen's work developing adjuvants to enhance vaccine efficacy.
Quick answers
Who was awarded contract 75N93020C00042?
75N93020C00042 was awarded to Antagen Biosciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.
How much is contract 75N93020C00042 worth?
The government has obligated $600,000 on 75N93020C00042.
Was contract 75N93020C00042 competed?
The extent of competition for 75N93020C00042 was full and open competition. The government received 12 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award